227 related articles for article (PubMed ID: 29901571)
21. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
[TBL] [Abstract][Full Text] [Related]
22. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Johnson DB; Bordeaux J; Kim JY; Vaupel C; Rimm DL; Ho TH; Joseph RW; Daud AI; Conry RM; Gaughan EM; Hernandez-Aya LF; Dimou A; Funchain P; Smithy J; Witte JS; McKee SB; Ko J; Wrangle JM; Dabbas B; Tangri S; Lameh J; Hall J; Markowitz J; Balko JM; Dakappagari N
Clin Cancer Res; 2018 Nov; 24(21):5250-5260. PubMed ID: 30021908
[No Abstract] [Full Text] [Related]
23. Indoleamine 2, 3-dioxygenase and B7-H1 expressions as prognostic and follow-up markers in human pancreatic carcinoma.
Wang L; Ma Q; Li D; Mu S; Li Y; Wang Y; Shi P; Yu H; Gao C; Guo K; Zhang Z
Pathol Res Pract; 2018 Sep; 214(9):1309-1314. PubMed ID: 30029936
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer.
Shi X; Wu S; Sun J; Liu Y; Zeng X; Liang Z
Sci Rep; 2017 Apr; 7():46209. PubMed ID: 28387300
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India.
Vallonthaiel AG; Malik PS; Singh V; Kumar V; Kumar S; Sharma MC; Mathur S; Arava S; Guleria R; Jain D
Ann Diagn Pathol; 2017 Dec; 31():56-61. PubMed ID: 29146060
[TBL] [Abstract][Full Text] [Related]
26. Distribution and Expression of Programmed Death Ligand -1 (PD-L1) in Non-Small Cell Carcinomas of the Lung in a Tertiary Care Centre in South India.
Jacob S
Turk Patoloji Derg; 2021; 37(2):139-144. PubMed ID: 33973642
[TBL] [Abstract][Full Text] [Related]
27. The role of the immunoescape in colorectal cancer liver metastasis.
Takasu C; Yamashita S; Morine Y; Yoshikawa K; Tokunaga T; Nishi M; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2021; 16(11):e0259940. PubMed ID: 34797860
[TBL] [Abstract][Full Text] [Related]
28. IL-27 induces the expression of IDO and PD-L1 in human cancer cells.
Carbotti G; Barisione G; Airoldi I; Mezzanzanica D; Bagnoli M; Ferrero S; Petretto A; Fabbi M; Ferrini S
Oncotarget; 2015 Dec; 6(41):43267-80. PubMed ID: 26657115
[TBL] [Abstract][Full Text] [Related]
29. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
Reddy OL; Shintaku PI; Moatamed NA
Diagn Pathol; 2017 Jun; 12(1):45. PubMed ID: 28623908
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
Parra ER; Villalobos P; Zhang J; Behrens C; Mino B; Swisher S; Sepesi B; Weissferdt A; Kalhor N; Heymach JV; Moran C; Zhang J; Lee J; Rodriguez-Canales J; Gibbons D; Wistuba II
J Thorac Oncol; 2018 Jun; 13(6):779-791. PubMed ID: 29526824
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas.
Zito Marino F; Rossi G; Montella M; Botti G; De Cecio R; Morabito A; La Manna C; Ronchi A; Micheli M; Salatiello G; Micheli P; Rocco D; Accardo M; Franco R
Am J Surg Pathol; 2020 Mar; 44(3):378-386. PubMed ID: 31688140
[TBL] [Abstract][Full Text] [Related]
32. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma].
Liu HQ; Zou BQ; Wang SY
Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):782-788. PubMed ID: 29136692
[No Abstract] [Full Text] [Related]
33. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
34. Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer.
Ye Q; Wang C; Xian J; Zhang M; Cao Y; Cao Y
Hum Pathol; 2018 May; 75():81-90. PubMed ID: 29447919
[TBL] [Abstract][Full Text] [Related]
35. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745
[TBL] [Abstract][Full Text] [Related]
36. High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.
Seeber A; Klinglmair G; Fritz J; Steinkohl F; Zimmer KC; Aigner F; Horninger W; Gastl G; Zelger B; Brunner A; Pichler R
Cancer Sci; 2018 May; 109(5):1583-1591. PubMed ID: 29498788
[TBL] [Abstract][Full Text] [Related]
37. Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors.
Samiei A; Gjertson DW; Memarzadeh S; Konecny GE; Moatamed NA
Diagn Pathol; 2022 Sep; 17(1):70. PubMed ID: 36104728
[TBL] [Abstract][Full Text] [Related]
38. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
